Eagle Pharmaceuticals Inc

NASDAQ:EGRX   3:59:59 PM EDT
46.94
+1.95 (+4.33%)
Products, Regulatory, Earnings Announcements

Eagle Pharmaceuticals Reports First Quarter 2022 Results

Published: 05/09/2022 13:45 GMT
Eagle Pharmaceuticals Inc (EGRX) - Eagle Pharmaceuticals Reports First Quarter 2022 Results.
Eagle Pharmaceuticals Inc - Q1 2022 Net Income Was $3.47 per Basic and $3.41 per Diluted Share.
Eagle Pharmaceuticals Inc - Qtrly Adjusted Non-GAAP Net Income Was $4.10 per Basic and $4.04 per Diluted Share.
Eagle Pharmaceuticals Inc - Q1 2022 Total Revenue Was $115.9 Million, Up From $41.2 Million in Q1 2021.
Eagle Pharmaceuticals Inc - Expects to Start Clinical Trial in Cal02 Patients in Q3 2022 During Pneumonia Season.
Eagle Pharmaceuticals Inc - Remains on Track to Support Submission of New Drug Application Later This Month for Landiolol, a Beta-1 Adrenergic Blocker.
Eagle Pharmaceuticals Inc - FY22 Adjusted Non-GAAP Research and Development Expense is Expected to Be in the Range of $46 Million to $50 Million.
Revenue is expected to be $116.89 Million
Adjusted EPS is expected to be $3.36

Next Quarter Revenue Guidance is expected to be $86.79 Million
Next Quarter EPS Guidance is expected to be $1.89

More details on our Analysts Page.